THEMISMED.BOTHEMISMED.BOBSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +13.69% | -26.70% | -20.66% | -33.34% | -3.92% |
| Gross Profit Growth | +16.56% | +54.54% | -21.73% | +10.92% | -45.36% |
| EBITDA Growth | -18.99% | -205.48% | -130.99% | -91.68% | +40.20% |
| Operating Income Growth | +20.57% | -233.26% | -147.20% | -138.58% | +20.31% |
| Net Income Growth | -92.95% | -245.47% | -157.60% | -125.30% | +1843.69% |
| EPS Growth | -92.50% | -245.83% | -157.46% | -125.16% | +1733.33% |
| EPS Diluted Growth | -92.50% | -245.83% | -157.46% | -125.16% | +1716.67% |
| Weighted Average Shares Growth | -5.95% | +0.02% | +0.32% | +0.53% | +6.41% |
| Weighted Average Shares Diluted Growth | -5.95% | +0.02% | +0.32% | +0.53% | +6.99% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -0.47% | +0.00% | -13.57% | +0.00% |
| Inventory Growth | +0.00% | +19.47% | +0.00% | +18.42% | +0.00% |
| Asset Growth | +0.00% | +3.82% | +0.00% | -3.27% | +0.00% |
| Book Value per Share Growth | +20.31% | +6.59% | +6.26% | -8.26% | +0.00% |
| Debt Growth | +0.00% | -13.37% | +0.00% | +17.32% | +0.00% |
| R&D Expense Growth | +0.00% | +3.22% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | -100.00% | -36.12% | -100.00% | -100.00% | +0.00% |